Submissions from 2025
Impact of UGT1A1∗28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3, Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M. O'Reilly, Zev A. Wainberg, and Mary L. B Peters
Individual participant data meta-analysis comparing neoadjuvant to perioperative chemoimmunotherapy in early-stage non-small cell lung cancer according to PD-L1 status, Jawad Alrawabdeh, Sunita Ghosh, Shahm Raslan, Alessandro Di Federico, Biagio Ricciuti, and Fawzi Abu Rous
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM), Rodabe N. Amaria, Herbert L. Duvivier, Katy K. Tsai, Parisa Momtaz, Robert W. Galamaga, Evan P. Pisick, Bently P. Doonan, Amy M. Weise, Natalie Langr, James D. Winkler, Harish P. Dave, Jennifer Robinson Diamond, and Ryan J. Sullivan
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC), Pedro C. Barata, Brian Rini, Toni Choueri, Sumanta Pal, Philippe Barthelemy, Roberto Iacovelli, Bradley A. McGregor, Laurence Albiges, Javier Molina-Cerrillo, Benjamin Garmezy, Ralph Hauke, Sheela Tejwani, Arnab Basu, Helen Moon, Katy Beckermann, Moshe Ornstein, Rana McKay, Claudia Lebedinsky, Edgar E. Braendle, and Robert Motzer
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide, Anne Bellon, Valentina Gambardella, Luis G. Paz-Ares, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad A. Bhatti, Pedro Rocha, Alice Ke, Frederic Massiere, Esteban R. Imedio, and Vito Dozio
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations, David R. Camidge, Nicolas Girard, Shun Lu, Shirish M. Gadgeel, Kristof Cuppens, Se-Hoon Lee, Hidehito Horinouchi, Tae Min Kim, Angelo Delmonte, Elvire Pons-Tostivint, Robert M. Jotte, Nivedita Aanur, Han Coburn, Qi Jiang, Theodore S. Jennaro, Tony Navas, Yan Li, and Jonathan W. Goldman
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma, Toni K. Choueiri, Moshe C. Ornstein, Pedro C. Barata, Marc R. Matrana, Jaime R. Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Christopher Negro, Jianfen Chen, Paul G. Foster, Manish Monga, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141), Toni Choueri, Moshe Ornstein, Pedro C. Barata, Marc Matrana, Jaime Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Chris Negro, Jianfen Chen, Paul Foster, Deepti Warad, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATENORTH AMERICA): NRG-GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher H. Lieu
Fusing quality improvement and education frameworks to reduce delays in tumor genotyping at community cancer centers, Carmine Deluca, Jeremy Stapp, Chris Kriz, Jessica Massey, Thomas Loss, Zyad Kafri, Michael Beyer, John Marshall, Yuan Ying, Jonathan Treisman, and Zeeshan Ali
Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S- 531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors, Toshihiko Doi, Taroh Satoh, Noboru Yamamoto, Clara Hwang, Omid Hamid, Anthony J. Olszanski, Feng Zeng, Takayuki Katsube, Michael J. Chisamore, and Tomohiko Harada
Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting, Shirish M. Gadgeel, Nima Nabavizadeh, Dax Kurbegov, Charles McDonnell III, James W. Lillard Jr., Marc Matrana, Alan Roth, Andrea Johnston, Sami Tahhan, Rami Owera, Matthew Margolis, Anuraag Kansal, Margarita Lopatin, Margaret McCusker, and Karthik V. Giridhar
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation, Valentina Gambardella, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Gonzalo Fernandez Hinojal, Jon Zugazagoitia, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad A. Bhatti, Pedro Rocha, Anna Vilalta-Lacarra, Esteban R. Imedio, Sandrine Micallef, Jonathan Wessen, Vito Dozio, Rikke F. Franzen, Anne Bellon, and Luis G. Paz-Ares
Treatment and outcomes of breast cancer with leptomeningeal disease: Real-world experience in the African American population, Bipin Ghimire, Maria Jamil, and Marian Girgis
Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience, Bipin Ghimire, Maria Jamil, Lisa R. Rogers, and Marian Girgis
MM-259: Impact of the International Myeloma Working Group (IMWG) SLiM Criteria on Multiple Myeloma Management: A Tertiary Care Center Experience, Dhairya Gor, Tasnim Rehman, Anju Pradeep, Sunita Ghosh, and Philip Kuriakose
298MO Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC, E. P. Hamilton, H. Han, N. Abuhadra, K. Kalinsky, N. P. McAndrew, A. Spira, N. Chan, K. Kelley, R. Parajuli, J. O'Shaughnessy, D. Starks, G. Wulf, Amy M. Weise, A. Chaudhry, J. S. Wang, D. L. Richardson, F. Meric-Bernstam, R. Burger, C. Bradshaw, and A. Giordano
Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4- directed dolasynthen antibody-drug conjugate, Erika P. Hamilton, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Nicholas P. McAndrew, Alexander I. Spira, Nancy Chan, David Starks, Gerburg M. Wulf, Arvind Chaudhry, Kristen Kelley, Ritesh Parajuli, Judy S. Wang, Joyce O'Shaughnessy, Amy M. Weise, Debra L. Richardson, Dario R. Roque, Renata Ferrarotto, Nora Zizlsperger, and Antonio Giordano
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Antonio Giordano, David Starks, Gerburg M. Wulf, Nicholas P. McAndrew, Joyce O'Shaughnessy, Alexander I. Spira, Nancy Chan, Kristen Kelley, Ritesh Parajuli, Amy M. Weise, Arvind Chaudhry, Judy S. Wang, Debra L. Richardson, Dario R. Roque, Funda Meric-Bernstam, Caroline Rogalski, and Erika P. Hamilton
Vascular heterogeneity influences treatment response in pancreatic cancer, Samantha B. Kemp, William B. Sullivan, Benjamin M. Kahn, Jonathan H. Sussman, Il-Kyu Kim, Takeshi Katsuda, Sidney Mahan, Margo I. Orlen, Samuel D. Zwernik, Kailee M. G, Steele Agnieszka K, Witkiewicz Erik S, Knudsen Ben Z, and Stanger #REF! #REF!
NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study, Xiuning Le, Zofia Piotrowska, Alexander I. Spira, Christina S. Baik, Maria Q. Baggstrom, Gerald S. Falchook, Joel W. Neal, Shirish M. Gadgeel, Gilberto Lopes, Melissa L. Johnson, Jonathan W. Riess, Danny Nguyen, Lisa Morelli, Danieska Sandino, Steven Margossian, Vivek Upadhyay, and Fernando Santini
Proteogenomic characterization of antibody-drug conjugate target expression profiles in transcriptional subtypes of small cell lung cancer, Edwin Lin, Mitch Singstock, Sanad Alhushki, Sameer S. Deshmukh, Changde Cheng, Kayla Goliwas, Jessy Deshane, Abdul R. Naqash, Fawzi Abu Rous, Rajat Thawani, and Aakash Desai
Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study, Gilberto Lopes, Justin F. Gainor, Vivek Subbiah, Daniel W. Bowles, Robert C. Doebele, Aaron S. Mansfield, Christina S. Baik, Shirish M. Gadgeel, Gregory P. Kalemkerian, Sai-Hong I. Ou, Carlos R. Becerra, Makenzi C. Evangelist, Stephen V. Liu, Jason M. Melear, Ashish Saxena, Amber Thomassen, Sophia Wang, and Benjamin Besse
The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC), Himil Mahadevia, Sharon Wu, Robert R. McWilliams, Umair Majeed, Jason S. Starr, Jeremy C. Jones, Osama M. MoSalem, Conor O'Donnell, Daniel H. Ahn, Joanne Xiu, Hani El Shawa, George W. Sledge Jr., Philip A. Philip, Ninad Kulkarni, Sanjay Goel, David Spetzler, Harshabad Singh, Mitesh J. Borad, Tanios S. Bekaii-Saab, and Hani M. Babiker
A phase II trial of tobemstomig (tobe) plus platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) plus chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC), E. Nadal, A. Rittmeyer, F. De Marinis, D. H. Lee, Shirish M. Gadgeel, N. Vilariño, E. Bria, S. Arulananda, E. H. Cronenberg, V. Antic, E. Bennett, Y. Hu, K. Madden-Raja, P. Williams, H. Prizant, and S. Popat
Benchmarking clinical reasoning and accuracy of large language models on breast oncology multiple-choice questions, Roupen Odabashian, Ameer S. Basta, Ritu Sidgal, Austin Chao, Trevor Lin, Wid Alhassani, Michael T. Aboujaoude, L. Henry Bryant III III, Gregory Dyson, Suha Soni, Padmapriya Muthu, Ali Haider, Hiba Jabbour Aida, Lubina Arjyal, Lawrence E. Flaherty, and Jailan Elayoubi
Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE), Joshua D. Palmer, Nathaniel J. Myall, Erin L. Schenk, Fawzi Abu Rous, Lai Wei, Carly Pilcher, Brian Spahnie, Charles D. Tobin, Kimberly Cameron, and Dwight H. Owen
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), Vincent J. Picozzi, Hani M. Babiker, Sreenivasa R. Chandana, Bohuslav Melichar, Anup Kasi, Gang Jin, Javier Gallego, Andrea J. Bullock, Hao Chunyi, Lucjan Wyrwicz, Arsen Osipov, Christelle De La Fouchardiere, Tomislav Dragovich, Woo Jin Lee, Kynan Feeney, Philip Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, and Teresa Macarulla
Inflammatory bowel disease and risk of cancer: A nationwide study, Abhishek Singh, Alamjeet K. Sindhu, Milan Khealani, Baris Tarimci, Ashima Gupta, Saarthak Malhotra, Pinank Bathvar, Vedant Shah, Simranjeet Bedi, Nyein W. Y Theik, Geetika Kukreja, and Sri U. J Obulareddy
Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC), Paulo Siqueira do Amaral, Aniko Szabo, Clara Hwang, Pooja Ghatalia, Abhishek Tripathi, Hannah Dzimitrowicz McManus, Hamid Emamekhoo, Jennifer King, Benjamin L. Maughan, Yousef Zakharia, Pedro C. Barata, Arpita Desai, Melissa A. Reimers, Yasser Ged, Elisabeth I. Heath, Mehmet A. Bilen, James Brugarolas, Brian I. Rini, Rana R. McKay, and Deepak Kilari
Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study, M. Wiesweg, Shirish M. Gadgeel, B. Cho, S. Lu, E. Felip, H. Hayashi, A. Spira, B. Besse, M. Thomas, S. Owen, Y. Kim, S. Lee, J. Mourao, Y. Lee, Y. Zhao, Y. Fang, N. Girard, Z. Liu, P. Sun, S. Cunha Souza Oliveira, H. Shen, L. Paz-Ares, S. Matsumoto, H. Tanaka, A. Ahmad, T. Andabekov, P. Sunpaweravong, Ö. Özyilkan, J. Yang, M. Gottfried, O. Hernandez, M. Kimmich, D. Cortinovis, and D. Kaen
MM-423: Secondary Hematologic Malignancies in Patients With Multiple Myeloma: A Retrospective Analysis of Risk Factors and Incidence in a Large Urban Health System, Markie Zimmer, Jamie T. C Abad, Jaya Gupta, Sunita Ghosh, and Philip Kuriakose
Submissions from 2024
Real-world outcomes in patients with biomarker-selected early-stage non-small cell lung cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam, Qing Zhang, Thomas Majda, Daniel Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, and Shirish M. Gadgeel
PP01.107 Patient Characteristics and Treatment Patterns in Biomarker Selected Early Non-Small Cell Lung Cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, and Shirish Gadgeel
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial, Joachim Aerts, Luis G. Paz-Ares, Carole Helissey, Federico Cappuzzo, Gilles Quere, Dariusz Kowalski, Jose Carlos Benitez Sr., Florian Guisier, Benjamin Besse, Shirish M. Gadgeel, Thomas Wehler, Ignacio Gil-Bazo, Michael Jon Chisamore, Cem Gorgun, Ilhan Celik, Marie Holst Mørch, Patricia Garrido Castro, Teng Jin Ong, and Enriqueta Felip
A comprehensive analysis of the molecular landscape of HER3 expression in adenocarcinoma of the lung, S. K. Alhushki, A. N. Al-Bzour, N. N. Al-Bzour, H. M. Abushukair, and Fawzi Abu Rous
PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection, Zaid Al-Saheli, Omar Ammari, Linda Albusoul, Fawzi Abu Rous, and Shirish Gadgeel
The Polymerase Epsilon Gene Expression and Mutation Predictive Significance in Patients Receiving Immune Checkpoint Inhibitors (icis) for Non-small Cell Lung Cancer (NSCLS), A. Alshurafa, S. Alhushki, D. Alfaqheri, H. Abushukair, B. N. Alzghoul, and Fawzi Abu Rous
Black/African American participation in cancer clinical trials: A qualitative study of community members, patients with cancer, and survivors (Detroit, MI) using CBPR, Sylvester Antwi, Linda Kaljee, Doreen Dankerlui, Eleanor M. Walker, Harriet Larrious-Lartey, Barbara Brush, Barbara Israel, Donna Harris, Sophia Chue, Nayomi Cawthome, Cassandra Mills, Valerie Ofori Aboah, Gwendolyn Daniels, Livingstone Aduse-Poku, Chris M. Coombe, Zachary Rowe, La'Toshia Patman, Wayne Ramocan, Denise White-Perkins, and Evelyn M. Jiagge
Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors, A. S. Azmi, M. H. Uddin, S. F. Bannoura, H. M. Khan, Maria Diab, S. Kim, E. Beal, M. Tobon, H. Chen, R. Beydoun, G. Dyson, R. M. Mohammad, Philip A. Philip, M. N. Al-Hallak, B. F. El-Rayes, and B. Pasche
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC), Julia L. Bachler, Anqi Wang, Laila Poisson, Eric Adjei Boakye, Samantha H. Tam, Shirish Gadgeel, Benjamin Movsas, and Bindu Potugari
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC), Julia L. Bachler, Anqi Wang, Laila M. Poisson, Eric Adjei Boakye, Samantha H. Tam, Shirish M. Gadgeel, Benjamin Movsas, and Bindu Potugari
1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours, B. Besse, A. E. Drilon, B. C. Cho, D. R. Camidge, J. Neal, C-C. Lin, S. V. Liu, M. Nagasaka, S. C-H Kao, E. Felip, A. J. Van Der Wekken, C. C. Lin, J. R. Bauman, Shirish Gadgeel, M. Samant, J. Shen, Y. Sun, V. W. Zhu, V. A. Upadhyay, and J. J. Lin
XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers, Robert Burger, Erika Hamilton, Sylvia Adams, Hyo Han, Alexander Spira, Antonio Giordano, Arvind Chaudhry, Ritesh Parajuli, Judy Wang, Amy Weise, Nour Abuhadra, Patrick McNamara, and Kevin Kalinsky
XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers, Robert Burger, Erika Hamilton, Sylvia Adams, Hyo Han, Alexander Spira, Antonio Giordano, Arvind Chaudhry, Ritesh Parajuli, Judy Wang, Amy Weise, Nour Abuhadra, Patrick McNamara, and Kevin Kalinsky
RGI-2001 with CNI-Based Prophylaxis Demonstrates Better Acute Gvhd-Free Survival Following Myeloablative Allohct without Increased Relapse: Comparison of a Multi-Center Phase 2b Study with a Contemporaneous CIBMTR Cohort, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean A. Yared, Markus Y. Mapara, Amer Assal, Hannah Choe, Zachariah DeFilipp, Dana D. Lee, Hayley Lane, Linda J. Burns, Mei-Jie Zhang, Matthew Bye, Ted A. Gooley, and Ayman Saad
Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1, A. C. Chiang, M. E. Olmedo Garcia, J. Carlisle, A. Dowlati, N. Reguart, E. Felip, P. J. Jost, N. Steeghs, R. Stec, Shirish Gadgeel, H. H. F Loong, W. Jiang, A. Hamidi, A. Parkes, and L. Paz-Ares
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC, Byoung Chul Cho, Omid Hamid, Xinhua Zhu, Bhumsuk Keam, John M. Kaczmar, Stephen K. Williamson, Ariel E. Birnbaum, Afshin Dowlati, Grace K. Dy, Steven Jeffrey Hager, Filipa Lynce, Raymond S. McDermott, Debashis Sarker, Amy M. Weise, Timothy A. Yap, Emrullah Yilmaz, Fang Fang, Jayakumar Mani, Glenn Scott Kroog, and Kyriakos P. Papadopoulos
Characterizing outcomes of biliary tract cancers (BTC) with b-catenin (CTNNB1) alterations, Lydia D. Chow, Diana L. Hanna, Rituparna Ganguly, Yasmine Baca, Jonathan Pai, Ani Misirian, Sandra Algaze, Mehmet Akce, Philip A. Philip, Syma Iqbal, Rachna T. Shroff, Heinz-Josef Lenz, Tanios S. Bekaii-Saab, and Anthony B. El-Khoueiry
INSIGHT INTO ATHN 16: TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS TO EVALUATE THE SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW, Tammuella Chrisentery-Singleton, Suchitra Acharya, Sanjay Ahuja, Lauren Amos, Meera Chitlur, Miguel Escobar, Ashley Eason, Shveta Gupta, Phillip Kuriakose, Sharon Pennington, Rajiv Pruthi, Michael Recht, Spencer Sullivan, Doris Quon, Allison Wheeler, and Mark Reding
Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castrationresistant prostate cancer (CRPC): A modular phase I trial, Brendan Connell, Clara Hwang, Edmund Folefac, Christian Lawlor, Benjamin Koethe, and Paul Mathew
HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NATIONWIDE ANALYSIS, John Cuenca, Bernard Moscoso, Diana Cardenas, Marissa Schettino, Daniel Gonzalez-Mosquera, Pool Tobar, Luis Gonzalez-Mosquera, and Joseph Nates
HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NATIONWIDE ANALYSIS, John Cuenca, Bernard Moscoso, Diana Cardenas, Marissa Schettino, Daniel Gonzalez-Mosquera, Pool Tobar, Luis Gonzalez-Mosquera, and Joseph Nates
Pulsed low dose rate radiation to mitigate tumor-permissive responses in pancreatic cancer-associated fibroblasts: Introducing the HOST-factor, Edna Cukierman, Janusz Franco-Barraza, Tiffany Luong, Kristopher Raghavan, Jessica K. Wong, Débora Barbosa Vendramini Costa, Ralph Francescone, Jaye C. Gardiner, Sanjay S. Reddy, Elizabeth A. Handorf, and Joshua E. Meyer
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATENORTH AMERICA): NRG- GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim H. H Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher H. Lieu
PS3-3 Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors, T. Doi, M. R. Patel, T. Koyama, G. S. Falchook, C. Friedman, S. A. Piha-Paul, M. Gutierrez, M. Awad, Ahmad Mattour, T. Satoh, S. Takahashi, T. Tsunoda, S. Kadowaki, Y. Watanabe, N. Okamoto, H. Goto, N. Yoshizuka, M. Qian, X. Qian, and M. Johnson
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours, A. E. Drilon, J. J. Lin, M. L. Johnson, C. S. Baik, L. G. Paz-Ares, B. Besse, J. Mazieres, A. Swalduz, A. R. Minchom, J. Reuss, Shirish Gadgeel, J. W. Riess, G. Liu, B. J. Solomon, D. R. Camidge, W. Swe, Y. Sun, J. Shen, V. W. Zhu, and E. Felip
Atezolizumab in patients (pts) with tumor mutational burden (TMB)-high tumors from the TAPISTRY trial, Rafal Dziadziuszko, Fabrice Barlesi, Jeong Eun Kim, Shirish M. Gadgeel, Maciej Krzakowski, Jae Ho Jeong, Gennaro Daniele, David Chen, Youyou Hu, Timothy R. Wilson, Brian P. Simmons, and David M. Thomas
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial, Rafal Dziadziuszko, Fabrice Barlesi, Jeong Eun Kim, Shirish M. Gadgeel, Maciej Krzakowski, Jae Ho Jeong, Gennaro Daniele, David Chen, Youyou Hu, Timothy R. Wilson, Brian P. Simmons, and David M. Thomas
Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study, R. Dziadziuszko, S. Damian, Shirish Gadgeel, E. Garralda, A. Italiano, J. E. Kim, M. Krzakowski, C-C. Lin, A. Popovtzer, D. Thomas, W. Kirschbrown, S. Patel, T. Pham, M. Sbirnac, F. Wu, and F. Barlesi
STREAMLINING THE STUDY INTAKE PROCESS AT THE CANCER CLINICAL AND TRANSLATIONAL RESEARCH OFFICE (CCTRO), Raid Faddah, Tobias Walbert, James Snyder, Shirish Gadgeel, Philip A. Philip, and Lisa M. Lange
Irf3 and Irf7 induce epigenetic changes to promote pancreatic carcinogenesis, Lisa Fahr, Simone Benitz, Nicole Schreiner, Tobias Straub, Jurik Mutter, Hannah Hamidach, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Andrea Terrasi, Gunnar Schotta, Axel Imhof, Kirsten Lauber, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, and Ivonne Regel
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors, Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O. Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P. Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, and Stefan K. Barta
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors, Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O. Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P. Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, Ashwin Gollerkeri, Jared Gollob, Aditi Shastri, and Stefan K. Barta
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study, Enriqueta Felip, Byoung Chul Cho, Vanesa Gutiérrez, Adlinda Alip, Benjamin Besse, Shun Lu, Alexander I. Spira, Nicolas Girard, Raffaele Califano, Shirish M. Gadgeel, James Chih-Hsin Yang, Naoyuki Nogami, Koichi Azuma, Joshua C. Curtin, Jiarui Zhang, Anesh Panchal, Mariah Ennis, Seema Niphadkar Sethi, Joshua Michael Bauml, and Se-Hoon Lee
689TiP A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors, V. Florou, D. Orr, A. Morton, Y. Cheng, P. Yuan, Y. Sun, X. Tang, S. Liu, and Shirish Gadgeel
P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Shirish M. Gadgeel, A. Rahman, U. Osaghae, T. M. Fernando, M. T. Lin, K. Koli, C. Meyenberg, M. Mathisen, and F. Skoulidis
P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Shirish Gadgeel, A. Rahman, U. Osaghae, T. M. Fernando, M. T. Lin, K. Koli, C. Meyenberg, M. Mathisen, and F. Skoulidis
1813TiP Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study, V. Gambardella, A. F. Navarro Mendivil, J. M. Lopez-Picazo Gonzalez, P. Jain, G. Fernandez-Hinojal, M. De Miguel, J. Zugazagoitia, Shirish Gadgeel, S. A. Bhatti, A. Vilalta, E. Castanon Alvarez, P. F. Simoes da Rocha, S. Micallef, R. Frederiksen Franzen, L. Piggott, A. Bellon, E. Rodrigo Imedio, and L. G. Paz-Ares
TIGIT expression increases with advancing clinical stages of resected pancreatic cancer, Madison George, Julie Clark, Kendyll Gartrelle, Georges Nassif, Kailee Hartway, Daniel Long, Daniel Salas-Escabillas, Allison Wombwell, Thais Pichardo, Hui-Ju Wen, Simone Benitz, Samuel Zwernik, Rupen Shah, Hakmin Park, Philip Philip, Gazala Khan, Howard Crawford, David Kwon, Brian Theisen, and Nina Steele
Longitudinal tissue-based evaluation of TIGIT expression in patients with pancreatic cancer: Effect of expression with advancing clinical stages and across racial groups, Madison George, Julie Clark, Kailee M. Hartway, Samuel Zwernik, Kendyll Gartrelle, Daniel Salas-Escabillas, Daniel Long, Georges Nassif, Thais Pichardo, Allison Wombwell, Hui-Ju Wen, Simone Benitz, Philip A. Philip, Gazala Khan, Rupen A. Shah, Hakmin Park, Howard C. Crawford, David S. Kwon, Brian Theisen, and Nina Steele
EP.13E.04 Racial Disparities in Genomic Subtypes of Small Cell Lung Cancer Patients, Manasi M. Godbole, Fawzi Abu Rous, Sunita Ghosh, Dhananjay Chitale, and Shirish Gadgeel
EP.13E.04 Racial Disparities in Genomic Subtypes of Small Cell Lung Cancer Patients, Manasi M. Godbole, Fawzi Abu Rous, Sunita Ghosh, Dhananjay Chitale, and Shirish M. Gadgeel
Factors influencing career choices and post-fellowship perspectives in adult hematology/oncology fellows: A nationwide cross-sectional study, Luis F. Gonzalez Mosquera, Nino Balanchivadze, Faria Ali, Matthew Meranda, Oscar Hinojosa Castro, and Philip Kuriakose
Abatacept with FluBu2: To Use or Not to Use, Luis F. Gonzalez-Mosquera, Klodiana Neme, Nancy Mikulandric, Izabela Mazur, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
The silent burden: A SEER-based analysis of potential years of life lost due to genitourinary cancers in the United States (1975-2017), Rajvi Gor, Pranav Gwalani, Dhairya Gor, Anand Shah, Rahul Kumar Thakur, and Benjamin Adam Gartrell
Pain, palliation, and opioid use patterns: A nationwide analysis of neoplasm-related pain admissions and trends (2016-2020), Rajvi Gor, Pranav Gwalani, Dhairya Gor, Anand Shah, Rahul Kumar Thakur, and Abhishek Kumar
PM2.5 and risk of lung cancer and associated mortality: An umbrella meta-analysis, Ashima Gupta, Abhishek Singh, Baris Tarimci, Alamjeet Kaur Sindhu, Pinank Bathvar, Simranjeet Bedi, Nyein Wint Yee Theik, Vedant Shah, Saarthak Malhotra, Milan Khealani, Sri Usha Jeevani Obulareddy, Geetika Kukreja, and Amaraja Kanitkar
Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises, Ashish O. Gupta, Akshay Sharma, Haydar Frangoul, Jignesh Dalal, Julie Kanter, Asif Alavi, John DiPersio, Mary Eapen, Jennifer J. Jaroscak, Ernesto Ayala, Edward D. Ziga, Stacey Rifkin-Zenenberg, Alex C. Minella, Guo Chen, Yinzhong Chen, Priya S. Chockalingam, Ling Lin, Marcelyne Joseney-Antoine, Leanne Ianniello, Beth Gardner, Adam J. Hartigan, Giuseppe Ciaramella, Sunita Goyal, Amy Simon, Alexis Thompson, and Matthew M. Heeney
Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises, Ashish O. Gupta, Akshay Sharma, Haydar Frangoul, Jignesh Dalal, Julie Kanter, Asif Alavi, John DiPersio, Mary Eapen, Jennifer J. Jaroscak, Ernesto Ayala, Edward D. Ziga, Stacey Rifkin-Zenenberg, Alex C. Minella, Guo Chen, Yinzhong Chen, Priya S. Chockalingam, Ling Lin, Marcelyne Joseney-Antoine, Leanne Ianniello, Beth Gardner, Adam J. Hartigan, Giuseppe Ciaramella, Sunita Goyal, Amy Simon, Alexis Thompson, and Matthew M. Heeney
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA), Christopher Hanyoung Lieu, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
SPATIAL LOCALIZATION OF MACROPHAGES AND CANCER-ASSOCIATED FIBROBLASTS IN PANCREATIC CANCER: IMPLICATIONS FOR MYELOID TARGETING STRATEGIES, Natalie K. Horvat, Emily Greene, Alyssa Krasinskas, Maria Diab, Shishir Maithel, Juan Sarmiento, Olatunji Alese, and Gregory B. Lesinski
195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity, H-D. Hummel, S. Champiat, M. E. Olmedo Garcia, M. Boyer, K. He, N. Steeghs, H. Izumi, M. L. Johnson, T. Yoshida, H. Bouchaab, A. Dowlati, H. Borghaei, E. Felip, P. J. Jost, Shirish Gadgeel, X. Chen, Y. Yu, P. Martinez, A. Parkes, and L. Paz-Ares
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3, Maen A. Hussein, Gazala Khan, Sreenivasa R. Chandana, Roberto A. Pazo Cid, Igor Kiss, Javier Gallego, Teresa Macarulla, Christelle De La Fouchardiere, Thorsten Goetze, Andrew P. Dean, Eileen M. O'Reilly, Zev A. Wainberg, Woo Jin Lee, Eric Van Cutsem, Richard Hubner, Andrew S. Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Fiona Maxwell, and Davide Melisi
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3, Maen A. Hussein, Gazala Khan, Sreenivasa R. Chandana, Roberto A. Pazo Cid, Igor Kiss, Javier Gallego, Teresa Macarulla, Christelle De La Fouchardiere, Thorsten Goetze, Andrew Peter Dean, Eileen M. O'Reilly, Zev A. Wainberg, Woo Jin Lee, Eric Van Cutsem, Richard Hubner, Andrew S. Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Fiona Maxwell, and Davide Melisi
1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study, D. Kilari, A. Szabo, M. A. Bilen, Y. Ged, B. L. Maughan, Clara Hwang, H. McManus, P. M. Coelho Barata, A. Desai, Y. Zakharia, H. Emamekhoo, A. Tripathi, T. Rose, P. Ghatalia, M. A. Reimers, E. Heath, J. M. King, B. I. Rini, J. Brugarolas, and R. R. McKay
Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study, D. Kilari, A. Szabo, M. A. Bilen, Y. Ged, B. L. Maughan, Clara Hwang, H. McManus, P. M. Coelho Barata, A. Desai, Y. Zakharia, H. Emamekhoo, A. Tripathi, T. Rose, P. Ghatalia, M. A. Reimers, E. Heath, J. M. King, B. I. Rini, J. Brugarolas, and R. R. McKay
1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety, V. S. Koshkin, P. Barthelemy, G. Gravis, O. Goodman, I. Duran, R. Girones Sarrio, Clara Hwang, J. Garcia-Donas, R. Morales Barrera, S. Zanetta, M. Chisamore, M. Liu, M. Gil, G. Tomlinson, H. Elsayed, and Y. Loriot
Standard Risk Assessment Tools Fall Short to Assess Risk in Transplant Patients, Radhika Kulkarni, Luis F. Gonzalez, Chun-Hui Lin, Courtney Rose, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti- PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial, Primo N. Lara Jr., Stew Kroll, Jonathan Alhaj Chatzkel, Deanna Gek Koon Teoh, Vincent T. Ma, Deepak Kilari, Clara Hwang, Randy F. Sweis, Kiran Yalamanchili, Julio A. Peguero, Tianhong Li, and Mamta Parikh
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002), Xiuning Le, Alexander I. Spira, Shirish M. Gadgeel, Jonathan W. Riess, Yan Yu, Yanqiu Zhao, Ying Cheng, Oscar Juan-Vidal, Bo Gao, Kiyotaka Yoh, Martin Forster, Satoru Kitazono, Hidetoshi Hayashi, David Planchard, Yong Jiang, Nichole Baio, Marcin Kowanetz, William Leung, Jerry Y. Hsu, and Jie Wang
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations, X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, Shirish M. Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A. J. de Langen, J. Mazieres, M. Pérol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, and J. Wang
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations, X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, Shirish Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A. J. de Langen, J. Mazieres, M. Pérol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, and J. Wang
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%, Melissa Lynne Johnson, Edurne Arriola, Terufumi Kato, Nicolas Girard, Shirish M. Gadgeel, Jie Wang, Xia Li, Caitlin Lowery, Lee M. Krug, and Myung-Ju Ahn
1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment, M. Mckean, Amy M. Weise, K. P. Papadopoulos, J. P. Crown, S. S. Thomas, J. M. Mehnert, J. Kaczmar, K. B. Kim, N. J. Lakhani, M. L. Yushak, J. Mani, F. Fang, L. Brennan, I. Lowy, M. E. Salvati, M. G. Fury, K. Lewis, and O. Hamid
The Mediating Effects of Racial and Social Health Disparities on Cancer Urgent Care Outcomes: An Urban Cancer Center Experience, Matthew Meranda, Madison Drallmeier, Sisira Kavuri, Jamie Abad, Aayush Mittal, Rida Farook, Muniza Hossain, Courtney Rose, Carl P. Wilson, Muhammad Shahid, Philip Kuriakose, and Ahmad H. Mattour
The Mediating Effects of Racial and Social Health Disparities on Cancer Urgent Care Outcomes: An Urban Cancer Center Experience, Matthew Meranda, Madison Drallmeier, Sisira Kavuri, Jamie Abad, Aayush Mittal, Rida Farook, Muniza Hossain, Courtney Rose, Carl Wilson, Muhammad Shahid, Philip Kuriakose, and Ahmad H. Mattour
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer, Van K. Morris II, Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zishuo I. Hu, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, and Philip A. Philip
MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA, D. Nguyen, B. Besse, B. C. Cho, S.-H. Lee, K. H. Lee, S. Lu, Y. Cheng, Y. Yao, N. Girard, C.-C. Lin, E. Felip, A. Aguilar, C. Charoentum, F. J. S. M. Cruz, M. Majem, C. S. Lim, H. Akamatsu, H. Hayashi, J. C.-H. Yang, R. Kowalyszyn, K. Tiscoski, F. Franke, D. Ponomarenko, C. Arslan, M. Forster, D. Urban, D. Misch, A. Delmonte, L. V. G. Montes, Shirish M. Gadgeel, M. Cruz-Correa, J. Peguero, and S. Rousey
MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA, D. Nguyen, B. Besse, B. C. Cho, S.-H. Lee, K. H. Lee, S. Lu, Y. Cheng, Y. Yao, N. Girard, C.-C. Lin, E. Felip, A. Aguilar, C. Charoentum, F. J./S./M Cruz, M. Majem, C. S. Lim, H. Akamatsu, H. Hayashi, J. C.-H Yang, R. Kowalyszyn, K. Tiscoski, F. Franke, D. Ponomarenko, C. Arslan, M. Forster, D. Urban, D. Misch, A. Delmonte, L. V./G Montes, Shirish M. Gadgeel, M. Cruz-Correa, J. Peguero, and S. Rousey
